The interferon gamma receptor 2 (IFNGR2) is a critical component of the IFN-γ receptor complex, mediating immune responses by facilitating signal transduction upon IFN-γ binding. As a type II cytokine receptor, IFNGR2 pairs with IFNGR1 to form a functional heterodimeric receptor. Upon ligand engagement, it activates the JAK-STAT signaling pathway, triggering the expression of genes involved in antimicrobial defense, immune regulation, and tumor surveillance.
IFNGR2 antibodies are essential tools for studying receptor expression, localization, and signaling mechanisms in immune cells, such as macrophages and T cells. They are widely used in research applications, including Western blotting, flow cytometry, and immunohistochemistry, to investigate IFN-γ-mediated immune dysregulation. Clinically, mutations in IFNGR2 are linked to rare primary immunodeficiency disorders, particularly Mendelian susceptibility to mycobacterial diseases (MSMD), where impaired IFN-γ signaling predisposes individuals to severe infections. Antibodies targeting IFNGR2 aid in diagnosing these genetic defects and elucidating their molecular basis.
Additionally, IFNGR2 antibodies have therapeutic potential, serving as blockers or agonists to modulate IFN-γ pathways in autoimmune diseases or cancer immunotherapy. Their specificity and utility in both basic and translational research underscore their importance in advancing immunology and precision medicine.